East and North Hertfordshire NHS Trust Mount Vernon Hospital
Welcome,         Profile    Billing    Logout  
 3 Trials 
8 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
CRIADO, Pilar LOPEZ
Neo-DREAM, NCT03567889: Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C Melanoma Patients

Recruiting
3
186
Europe, US
Daromun, Surgery, Adjuvant therapy
Philogen S.p.A.
Melanoma Stage IIIB/C
06/24
06/26
PEACE2, NCT01952223 / 2012-000566-38: A Phase III of Cabazitaxel and Pelvic Radiotherapy in Localized Prostate Cancer and High-risk Features of Relapse

Active, not recruiting
3
761
Europe
Cabazitaxel, jevtana, Pelvic radiotherapy, prostate radiotherapy
UNICANCER, Sanofi
Adenocarcinoma of Prostate, Progression of Prostate Cancer
12/25
07/41
KEYNOTE-E72, NCT06016920: Safety and Efficacy of VB10.16 and Pembrolizumab in Patients With Head-Neck Squamous Cell Carcinoma

Recruiting
1/2
51
Europe, RoW
VB10.16, Pembrolizumab, KEYTRUDA®
Nykode Therapeutics ASA, Merck Sharp & Dohme LLC
HPV Positive Oropharyngeal Squamous Cell Carcinoma, HNSCC
09/27
01/28
Bratland, Ã…se
JADE, NCT06256588: A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

Recruiting
3
864
Europe, Canada, Japan, US, RoW
Dostarlimab, Placebo
GlaxoSmithKline
Neoplasms, Head and Neck
05/28
07/29
CA209-686_REPORT, NCT03317327: REirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck Tumors

Recruiting
1/2
20
Europe
Nivolumab, Opdivo, Radiotherapy (RT)
Oslo University Hospital, Bristol-Myers Squibb
Head and Neck Squamous Cell Carcinoma
11/23
11/40
KEYNOTE-E72, NCT06016920: Safety and Efficacy of VB10.16 and Pembrolizumab in Patients With Head-Neck Squamous Cell Carcinoma

Recruiting
1/2
51
Europe, RoW
VB10.16, Pembrolizumab, KEYTRUDA®
Nykode Therapeutics ASA, Merck Sharp & Dohme LLC
HPV Positive Oropharyngeal Squamous Cell Carcinoma, HNSCC
09/27
01/28
Khalique, Saira
NCT05456685: Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

Checkmark Data from trial in combination with carboplatin for platinum-sensitive epithelial ovarian cancer at IGCS 2022
Sep 2022 - Oct 2022: Data from trial in combination with carboplatin for platinum-sensitive epithelial ovarian cancer at IGCS 2022
Active, not recruiting
2
125
Europe, Canada, US, RoW
Mirvetuximab soravtansine, MIRV, IGN853, Carboplatin
ImmunoGen, Inc.
High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
06/25
12/26
KEYNOTE-E72, NCT06016920: Safety and Efficacy of VB10.16 and Pembrolizumab in Patients With Head-Neck Squamous Cell Carcinoma

Recruiting
1/2
51
Europe, RoW
VB10.16, Pembrolizumab, KEYTRUDA®
Nykode Therapeutics ASA, Merck Sharp & Dohme LLC
HPV Positive Oropharyngeal Squamous Cell Carcinoma, HNSCC
09/27
01/28

Download Options